863918-78-9 Usage
Uses
Used in Alzheimer's Disease Research:
Methoxy-X04 is used as a diagnostic tool for Alzheimer's disease, enabling the detection and quantification of amyloid plaques and neurofibrillary tangles in the brain. Its ability to cross the blood-brain barrier and bind selectively to Aβ aggregates makes it a valuable asset in studying the progression of the disease and evaluating potential therapeutic interventions.
Used in Drug Development:
Methoxy-X04 is used as a small molecule Aβ-binding agent in the development of anti-amyloid therapies for Alzheimer's disease. Its high binding affinity and brain permeability make it a promising candidate for the design of drugs that can target and reduce the accumulation of amyloid plaques, potentially slowing the progression of the disease.
Used in Imaging Techniques:
Methoxy-X04 is used as a fluorescent probe in advanced imaging techniques such as two-photon imaging. This allows researchers to visualize Aβ plaques in living APP/PS1 mice, providing insights into the spatial distribution and dynamics of amyloid deposits in the brain. This capability is crucial for understanding the pathophysiology of Alzheimer's disease and for monitoring the effects of potential treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 863918-78-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,3,9,1 and 8 respectively; the second part has 2 digits, 7 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 863918-78:
(8*8)+(7*6)+(6*3)+(5*9)+(4*1)+(3*8)+(2*7)+(1*8)=219
219 % 10 = 9
So 863918-78-9 is a valid CAS Registry Number.
863918-78-9Relevant academic research and scientific papers
Polyfluorinated bis-styrylbenzenes as amyloid-β plaque binding ligands
Nabuurs, Rob J.A.,Kapoerchan, Varsha V.,Metaxas, Athanasios,De Jongh, Sanne,De Backer, Maaike,Welling, Mick M.,Jiskoot, Wim,Windhorst, Albert D.,Overkleeft, Hermen S.,Van Buchem, Mark A.,Overhand, Mark,Van Der Weerd, Louise
, p. 2469 - 2481 (2014/05/06)
Detection of cerebral β-amyloid (Aβ) by targeted contrast agents remains of great interest to aid the in vivo diagnosis of Alzheimer's disease (AD). Bis-styrylbenzenes have been previously reported as potential Aβ imaging agents. To further explore their potency as 19F MRI contrast agents we synthetized several novel fluorinated bis-styrylbenzenes and studied their fluorescent properties and amyloid-β binding characteristics. The compounds showed a high affinity for Aβ plaques on murine and human brain sections. Interestingly, competitive binding experiments demonstrated that they bound to a different binding site than chrysamine G. Despite their high logP values, many bis-styrylbenzenes were able to enter the brain and label murine amyloid in vivo. Unfortunately initial post-mortem 19F NMR studies showed that these compounds as yet do not warrant further MRI studies due to the reduction of the 19F signal in the environment of the brain.
